Bioversys N
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
BIOV | SW
Overview
Corporate Details
- ISIN(s):
- CH0210362643 (+1 more)
- LEI:
- 894500UFIGC75NPZEZ68
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.bioversys.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Bioversys is a clinical-stage biopharmaceutical company dedicated to the research and development of novel small-molecule therapeutics to combat the global threat of Antimicrobial Resistance (AMR). The company specializes in developing drugs that utilize novel modes of action to target life-threatening, drug-resistant bacteria. Its clinical pipeline addresses high-priority pathogens and includes candidates for serious hospital-acquired infections (BV100), multi-drug resistant Tuberculosis (Alpibectir), and S. aureus infections (BV200). By targeting novel bacterial pathways, Bioversys aims to provide innovative solutions for significant unmet medical needs in infectious diseases.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Bioversys N and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-10 07:00 |
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 24.8 KB | |
| 2025-09-10 02:00 |
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 23.3 KB | |
| 2025-09-10 00:00 |
Interim Report
BioVersys Half Year Report 2025
|
English | 1.8 MB | |
| 2025-08-27 07:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 21.9 KB | |
| 2025-08-27 02:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 15.9 KB | |
| 2025-07-02 07:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 21.3 KB | |
| 2025-07-02 02:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 16.1 KB | |
| 2025-06-30 07:00 |
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
|
English | 10.5 KB | |
| 2025-06-30 02:00 |
Post-Annual General Meeting Information
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
|
English | 6.9 KB | |
| 2025-06-03 07:00 |
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.6 KB | |
| 2025-06-03 02:00 |
Pre-Annual General Meeting Information
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 20…
|
English | 11.0 KB | |
| 2025-04-30 00:00 |
Investor Presentation
BioVersys Corporate Presentation
|
English | 3.2 MB | |
| 2025-04-28 07:00 |
Regulatory News Service
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 8.5 KB | |
| 2025-04-28 02:00 |
Report Publication Announcement
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associa…
|
English | 7.2 KB | |
| 2025-04-08 07:00 |
Regulatory News Service
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
|
English | 29.7 KB |
Automate Your Workflow. Get a real-time feed of all Bioversys N filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Bioversys N via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
